After reviewing notable safety considerations for systemic and topical Janus kinase inhibitors for patients with atopic dermatitis, Nicole Keeter, PA-C, describes steps she has taken to become more comfortable prescribing these agents to her patients with AD and discusses important tips for counseling these patients on adverse events and black box warnings.